PROSCA/BLADDR 2022 | APCCC 2022: PSMA-PET, adjuvant radiotherapy vs early salvage radiotherapy

The Advanced Prostate Cancer Consensus Conference (APCCC) 2022 provided a forum for the discussion and debate of current concerns in the clinical management of men with advanced prostate cancer. Silke Gillessen, MD, PhD, University of Lugano and the Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, discusses key takeaways from the APCCC 2022 meeting, including the use of novel imaging for staging, as well as the role of adjuvant radiotherapy. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR 2022) in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.